Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT05469165

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Led by Laval University · Updated on 2023-11-15

214

Participants Needed

1

Research Sites

219 weeks

Total Duration

On this page

Sponsors

L

Laval University

Lead Sponsor

C

Canadian Institutes of Health Research (CIHR)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.

CONDITIONS

Official Title

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 80 years with a first episode of STEMI and documented coronary obstruction
  • Left ventricular ejection fraction (LVEF) less than 50% with mitral tenting area of 4 cm2 or more, OR LVEF 40% or less with inferior/posterior wall motion anomaly, OR LVEF 30% or less with wall motion in any territory
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Hemodynamic instability, cardiogenic shock, or papillary muscle rupture
  • Prior mitral valve surgery or procedures
  • Permanent atrial fibrillation that limits imaging and MR quantification
  • Primary mitral valve disease such as endocarditis, rheumatic, degenerative, or congenital
  • More than mild valvular disease other than mitral valve at baseline
  • Planned cardiac surgery like CABG or valve intervention within 3 months
  • Contraindications for MRI
  • Current treatment with selective serotonin reuptake inhibitors (SSRIs)
  • Chronic use of sedative medications
  • Ongoing or planned pregnancy
  • Chronic kidney failure with eGFR below 30 mL/min
  • Neurocognitive disorders
  • History or symptoms of urinary obstruction or glaucoma (relative contraindications for cyproheptadine)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval

Québec, Canada, G1V 4G5

Actively Recruiting

Loading map...

Research Team

J

Jonathan Beaudoin, MD

CONTACT

O

Ons Marsit, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here